Selinexor | Inhibitor of the nuclear export receptor CRM1/XPO1
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $65.00 | ||
| 25 mg | $205.00 |
Selinexor (1393477-72-9) is a potent inhibitor of the nuclear export receptor, chromosome region maintenance 1 (CRM1; Exportin-1 (XPO1)). It exhibited potent growth suppression in various T-cell acute lymphoblastic leukemia (T-ALL) cells (IC50’s = 34-203 nM)1 and pancreatic cancer cells (IC50 ~ 150 nM)2. Selinexor is being investigated as a possible chemotherapeutic in treating multiple types of cancer.3-8 Currently in clinical trials.
References/Citations:
1) Etchin et al. (2013), KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-ALL and AML; Br. J. Haematol. 161 117
2) Azmi et al. (2013), Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice; Gastroenterology 144 447
3) Desisto et al. (2019), Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-kB pathway in preclinical models of pediatric high-grade glioma; Mol. Cancer Ther. 19 540
4) Aboukameel et al. (2018), Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression; Oncotarget 9 35327
5) Baek et al. (2018), XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies; Oncotarget 9 34567
6) Wahba et al. (2018), The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo; Mol. Cancer Ther. 17 1717
7) Arango et al. (2017), Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer; Breast Cancer Res. 19 93
8) Conforti et al. (2017), Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors; Cancer Res. 77 5614
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Selinexor (1393477-72-9) is a potent inhibitor of the nuclear export receptor, chromosome region maintenance 1 (CRM1; Exportin-1 (XPO1)). It exhibited potent growth suppression in various T-cell acute lymphoblastic leukemia (T-ALL) cells (IC50’s = 34-203 nM)1 and pancreatic cancer cells (IC50 ~ 150 nM)2. Selinexor is being investigated as a possible chemotherapeutic in treating multiple types of cancer.3-8 Currently in clinical trials.
References/Citations:
1) Etchin et al. (2013), KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-ALL and AML; Br. J. Haematol. 161 117
2) Azmi et al. (2013), Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice; Gastroenterology 144 447
3) Desisto et al. (2019), Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-kB pathway in preclinical models of pediatric high-grade glioma; Mol. Cancer Ther. 19 540
4) Aboukameel et al. (2018), Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression; Oncotarget 9 35327
5) Baek et al. (2018), XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies; Oncotarget 9 34567
6) Wahba et al. (2018), The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo; Mol. Cancer Ther. 17 1717
7) Arango et al. (2017), Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer; Breast Cancer Res. 19 93
8) Conforti et al. (2017), Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors; Cancer Res. 77 5614
Related products
-
AAL-993 | VEGFR inhibitor
From $75.00CAS:269390-77-4Catalog Number:10-1034Activity:VEGFR inhibitorChemical Name:2-[(4-Pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamideMolecular Weight:371.36Molecular Formula:C20H16F3N3OSolubility:Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml).Physical Properties:Pale yellow solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
Mirin | Mre11-Rad50-Nbs1 inhibitor
From $50.00CAS:299953-00-7Catalog Number:10-1069Activity:Mre11-Rad50-Nbs1 inhibitorChemical Name:5-(4-Hydroxybenzylidene)-2-imino-1,3-thiazolidin-4-oneMolecular Weight:220.25Molecular Formula:C10H8N2O2SSolubility:Soluble in DMSO (up to 20 mg/ml).Physical Properties:Tan solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
17-AAG | HSP90 inhibitor
From $35.00CAS:75747-14-7Catalog Number:10-1097Activity:HSP90 inhibitorChemical Name:17-(Allylamino)-17-desmethoxygeldanamycinMolecular Weight:585.7Molecular Formula:C31H43N3O8Solubility:Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 5 mg/ml).Physical Properties:Purple or dark red solidPurity:>98% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Protect from moisture. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
